Cabozantinib: Treatment For Castration-Resistant Prostate Cancer That Has Metastasized To The Bone

Cabozantinib is a drug that inhibits genes involved in tumor growth, invasion, metastasis and angiogenesis (via VEGFR2). In this trial, 74% of the patients had disease regression and some patients had major complete or partial resolution of prostate cancer tumors that had metastasized to the bone. I like this drug because it provides a viable option for men with metastatic, castration-resistant prostate cancer, regardless of whether they have received prior docetaxel-based chemotherapy or not.
The latest Update on XL184 (cabozantinib) for Prostate Cancer.

Speak Your Mind